Top Section
Explore Business Standard
Don’t miss the latest developments in business and finance.
The Indian Institute of Technology Kanpur on Friday said it has licensed a gene therapy technology that has the potential to treat many hereditary eye diseases to Reliance Life Sciences Pvt Ltd. The gene therapy technology from IIT Kanpur will be further developed as an indigenous product by Reliance Life Sciences. Developed by Jayandharan Giridhara Rao and Shubham Maurya from the Department of Biological Sciences and Bioengineering (BSBE), IIT Kanpur, the patented technology modifies the gene of an organism to treat a hereditary disorder, the institute said in a statement. "Gene therapy using viral vectors has recently emerged as a potent tool in the field of molecular medicine. "We believe that this technology holds great promise for treating a wide range of hereditary eye diseases including Leber congenital amaurosis, an eye disorder that is present from birth and Retinitis pigmentosa, a disease causing progressive sustained vision loss," IIT Kanpur Director Abhay Karandikar ...
CSL Behring's Hemgenix, administered just once, cut the number of bleeding events expected over the course of a year by 54%, a key study of the therapy found
ImmunoACT, backed by Laurus Labs is testing their cancer product
Researchers used a genetic engineering strategy to reduce levels of tau--a key protein that accumulates and tangles in brain during the development of Alzheimer's--in an animal model of the condition
Putting aside prices for a moment, it's been an exciting period for medical progress
The Swiss drugmaker said last week that it was in the process of 'exiting' the Avexis scientists responsible for the manipulation of data on gene therapy Zolgensma
The approval of Spark Therapeutics Inc's Luxturna therapy would pave the way for new payment models for drugs, particularly in the US
The key to making the therapy work? One of medicine's greatest villains: HIV